NEW YORK – Swiss diagnostic firm Calciscon announced Thursday it has closed a $650,000 pre-series A financing round and will prepare for series A financing.
After this round, the total equity investment in Calciscon is $2.7 million.
This funding round will allow the firm to begin selling its T50 Calcification Propensity blood test, an in vitro diagnostic that assesses the tendency for vascular calcification in patients with chronic kidney disease. It provides "previously unavailable information" about the risk of cardiovascular disease in these patients so therapies can be better targeted, Calciscon said.
The T50 test is commercially available in Switzerland, and the firm said in a statement it will extend availability of the test to neighboring countries soon.
The Bern, Switzerland-based company is also preparing its series A financing round to launch the test for early adopters in additional countries and upgrade the T50 instrument into an automated desktop device, it said.